SFI
ARCT icon

Susquehanna Fundamental Investments’s Arcturus Therapeutics ARCT Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-11,940
Closed -$177K – 1192
2022
Q3 		$177K Buy
+11,940
New +$200K ﹤0.01% 1276
2022
Q1 		$751K Sell
27,841
-5,300
-16% -$135K 0.01% 936
2021
Q4 		$1.23M Buy
33,141
+16,040
+94% +$654K 0.03% 574
2021
Q3 		$817K Hold
17,101
– – 0.02% 961
2021
Q2 		$579K Buy
+17,101
New +$579K 0.01% 1097

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna Fundamental Investments's ARCT Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Arcturus Therapeutics (ARCT) in Q4 2022, closing a stake of 11,940 shares — an estimated $177K sold.

Susquehanna Fundamental Investments first reported a position in ARCT in Q2 2021 and held it in 5 quarters. The position peaked at $1.23M in Q4 2021. 113 funds tracked by Wall St. Rank hold ARCT as of Q4 2022.

  • Susquehanna Fundamental Investments reported no remaining Arcturus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 11,940 Arcturus Therapeutics shares in Q4 2022, an estimated $177K.
  • Susquehanna Fundamental Investments first reported a position in Arcturus Therapeutics in Q2 2021 and held it in 5 quarters.
  • Susquehanna Fundamental Investments's Arcturus Therapeutics position peaked at $1.23M in Q4 2021.
  • 113 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.